Balchem (NASDAQ:BCPC - Get Free Report) had its price objective increased by equities research analysts at HC Wainwright from $185.00 to $190.00 in a report released on Monday, Benzinga reports. The firm currently has a "buy" rating on the basic materials company's stock. HC Wainwright's price target suggests a potential upside of 10.14% from the company's previous close.
Separately, StockNews.com upgraded Balchem from a "hold" rating to a "buy" rating in a research report on Monday, October 28th.
View Our Latest Research Report on Balchem
Balchem Stock Performance
Shares of BCPC stock traded up $1.05 during mid-day trading on Monday, hitting $172.51. The stock had a trading volume of 97,863 shares, compared to its average volume of 107,808. The firm has a market cap of $5.61 billion, a PE ratio of 46.09, a PEG ratio of 5.12 and a beta of 0.65. The company's 50-day simple moving average is $171.71 and its 200-day simple moving average is $163.21. The company has a debt-to-equity ratio of 0.21, a current ratio of 2.98 and a quick ratio of 1.90. Balchem has a fifty-two week low of $116.84 and a fifty-two week high of $186.03.
Institutional Trading of Balchem
A number of institutional investors have recently added to or reduced their stakes in the stock. nVerses Capital LLC acquired a new stake in shares of Balchem during the 3rd quarter valued at approximately $35,000. Bessemer Group Inc. boosted its position in Balchem by 568.9% during the first quarter. Bessemer Group Inc. now owns 301 shares of the basic materials company's stock worth $47,000 after purchasing an additional 256 shares in the last quarter. GAMMA Investing LLC grew its holdings in Balchem by 73.4% in the third quarter. GAMMA Investing LLC now owns 841 shares of the basic materials company's stock valued at $148,000 after purchasing an additional 356 shares during the last quarter. Blue Trust Inc. increased its position in shares of Balchem by 642.5% in the third quarter. Blue Trust Inc. now owns 839 shares of the basic materials company's stock valued at $148,000 after buying an additional 726 shares in the last quarter. Finally, TD Asset Management Inc acquired a new position in shares of Balchem during the 2nd quarter worth $200,000. Hedge funds and other institutional investors own 87.91% of the company's stock.
About Balchem
(
Get Free Report)
Balchem Corporation develops, manufactures, and markets specialty performance ingredients and products for the nutritional, food, pharmaceutical, animal health, medical device sterilization, plant nutrition, and industrial markets worldwide. It operates through three segments: Human Nutrition and Health, Animal Nutrition and Health, and Specialty Products.
Read More
Before you consider Balchem, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Balchem wasn't on the list.
While Balchem currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
